ABL Lawyers Advise Underwriters of AnPac on its IPO on Nasdaq2020-01-315506
AnPac Bio-Medical Science Co., Ltd. (hereinafter referred to as “AnPac”), represented by ABL Lawyers, officially landed on Nasdaq Global Market on January 31, 2020 under the ticker symbol “ANPC”. AnPac is expected to raise $16 million through its American Depositary Shares ("ADS") at a price of $12 per ADS.
AnPac is a biotechnology company focusing on early cancer screening and detection. AnPac markets and sells a multi-cancer screening and detection test that uses its innovative, patented cancer differentiation analysis, or CDA, technology and its proprietary cancer-detection device, or CDA device. In addition to early cancer screening and detection, CDA technology has demonstrated potential to assist physicians in cancer diagnosis, prognosis and recurrence.
The AllBright legal team, led by senior partner Steve Zhu and included partner Frank Xu, partner Joy Huang, associate Ken Lin served as the legal counsels to Westpark Capital and Univest Securities LLC., the underwriters of this IPO and Nasdaq listing and advised on PRC legal matters.